Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $45.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 140.77% from the company’s current price.

A number of other brokerages have also recently weighed in on ORKA. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 price objective for the company. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Trading Up 1.0 %

ORKA opened at $18.69 on Monday. Oruka Therapeutics has a 52-week low of $18.20 and a 52-week high of $53.88. The stock’s 50 day simple moving average is $25.86. The stock has a market capitalization of $654.15 million, a P/E ratio of -2.98 and a beta of 0.87.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $1,037,000. FMR LLC acquired a new position in Oruka Therapeutics during the third quarter worth $114,763,000. Great Point Partners LLC acquired a new position in Oruka Therapeutics during the third quarter worth $12,614,000. Braidwell LP acquired a new position in Oruka Therapeutics during the third quarter worth $12,640,000. Finally, Janus Henderson Group PLC acquired a new position in Oruka Therapeutics during the third quarter worth $5,840,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.